The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
Subscribe To Our Newsletter & Stay Updated
